来那度胺与硼替佐米、地塞米松联合治疗多发性骨髓瘤患者临床效果观察  

Clinical effect of lenalidomide combined with bortezomib and dexamethasone in the treatment of multiple myeloma

作　　者：肖瑾 孙富英 杨晓哲[1] XIAO Jin;SUN Fuying;YANG Xiaozhe(Department of Hematology,Puyang People's Hospital,Puyang Henan 457000,China)

机构地区：[1]濮阳市人民医院血液内科,河南濮阳457000

出　　处：《天津药学》2025年第2期194-197,共4页Tianjin Pharmacy

摘　　要：目的探讨来那度胺与硼替佐米、地塞米松联合治疗多发性骨髓瘤(MM)患者临床效果。方法选取2019年5月至2024年7月濮阳市人民医院收治的102例MM患者,按随机数字表法分两组,各51例。对照组给予硼替佐米、地塞米松联合沙利度胺治疗,观察组予以硼替佐米、地塞米松联合来那度胺。对比两组临床疗效、免疫功能、生活质量及不良反应发生情况。结果观察组总有效率为94.12%,高于对照组的80.39%;CD3^(+)为(60.67±5.14)%、CD4^(+)为(39.24±3.66)%,高于对照组的(55.82±5.06)%、(35.79±3.45)%;CD8^(+)为(22.46±2.38)%,低于对照组的(25.24±2.47)%;健康调查问卷(SF-36)中的情感职能(69.51±5.40)分、社会功能(66.73±4.32)分、生命活力(70.20±5.17)分、心理健康(72.64±4.62)分、精神健康(75.42±6.25)分、生理功能(60.41±6.62)分、生理职能(65.15±6.85)分、躯体疼痛(67.97±6.64)分,高于对照组的(61.74±5.15)分、(58.78±5.42)分、(64.75±6.22)分、(66.10±4.23)分、(68.91±5.10)分、(52.64±5.45)分、(57.14±6.26)分、(60.84±6.57)分,有统计学差异(P<0.05);两组不良反应发生率比较,无统计学差异(P>0.05)。结论来那度胺与硼替佐米、地塞米松联合治疗MM,可增强临床疗效,促进免疫功能恢复,改善生活质量,不良反应少。Objective To explore the clinical effect of lenalidomide combined with bortezomib and dexamethasone in the treatment of patients with multiple myeloma(MM).Methods 102 patients with MM admitted to Puyang people's Hospital from May 2019 to July 2024 were randomly divided into two groups,with 51 cases in each group.The control group was treated with bortezomib,dexamethasone and thalidomide,while the observation group was treated with bortezomib,dexamethasone and lenalidomide.The clinical efficacy,immune function,quality of life and adverse reactions of the two groups were compared.Results The total effective rate of the observation group was 94.12%,higher than 80.39%of the control group;CD3^(+)was(60.67±5.14)%,CD4^(+)was(39.24±3.66)%,which were higher than(55.82±5.06)%,(35.79±3.45)%of the control group;CD8^(+)was(22.46±2.38)%,which was lower than(25.24±2.47)%of the control group;emotional function(69.51±5.40),social function(66.73±4.32),vitality(70.20±5.17),mental health(72.64±4.62),mental health(75.42±6.25),physiological function(60.41±6.62),physiological function(65.15±6.85)and physical pain(67.97±6.64)in the observation group were higher than those in the control group[(61.74±5.15),(58.78±5.42),(64.75±6.22),(66.10±4.23),(68.91±5.10),(52.64±5.45),(57.14±6.26)and(60.84±6.57)](P<0.05);There was no statistically significant difference in adverse reactions between the two groups(P>0.05).Conclusion Lenalidomide combined with bortezomib and dexamethasone in the treatment of MM can enhance the clinical efficacy,promote the recovery of immune function,improve the quality of life,and have fewer adverse reactions.

关 键 词：多发性骨髓瘤 来那度胺 硼替佐米 地塞米松 临床疗效 免疫功能 

分 类 号：R733.3[医药卫生—肿瘤]